Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

The study designs and dose-finding strategies that have dominated decades of oncology drug development are becoming obsolete as the FDA’s Project Optimus takes full effect. The agency is now heavily scrutinizing Phase 1 and 2 studies to see whether they identify the safest and most effective dose—while this change seems abrupt, it’s loomed over the field for a long time.

We’ve helped our clients adapt to the new standards with five best practices outlined in this article.


Open PDF

Return to Insights Center

Related Insights

Webinar

Advancing mRNA-based drug development and vaccine manufacturing

Jul 1, 2024

Blog

Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications

Feb 4, 2025

Article

Q&A Project Optimus: What you need to know

Oct 11, 2022

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Blog

PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers

Oct 4, 2024

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022

Webinar

Navigating the complexities of AML drug development

Oct 30, 2024

Webinar

Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)

Nov 12, 2024

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Webinar

How to navigate China’s regulatory environment

Feb 15, 2023

Related Insights

Webinar

Advancing mRNA-based drug development and vaccine manufacturing

Jul 1, 2024

Blog

Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications

Feb 4, 2025

Article

Q&A Project Optimus: What you need to know

Oct 11, 2022

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Blog

PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers

Oct 4, 2024

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022

Show more